Insight Molecular Diagnostics Inc (IMDX) (Q3 2026) Earnings Call Highlights: FDA Setback, ...
Insight Molecular Diagnostics Inc (IMDX) faces a tighter FDA response deadline and delayed kidney test approval, but sees momentum in its Galactic Registry, rapid Graftassure turnaround, and a Related Stocks: IMDX ,